EPIGENOMICS AG NA O.N. (ECX.F)
- Previous Close
1.5150 - Open
1.5550 - Bid 1.5600 x --
- Ask 1.6950 x --
- Day's Range
1.5550 - 1.5550 - 52 Week Range
1.4850 - 5.2500 - Volume
1,551 - Avg. Volume
120 - Market Cap (intraday)
1.327M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Mar 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.32
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. The company was founded in 1998 and is headquartered in Berlin, Germany.
www.epigenomics.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: ECX.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ECX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ECX.F
Valuation Measures
Market Cap
1.29M
Enterprise Value
-1.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.83
Price/Book (mrq)
0.68
Enterprise Value/Revenue
-4.33
Enterprise Value/EBITDA
0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.46%
Return on Equity (ttm)
--
Revenue (ttm)
339.23k
Net Income Avi to Common (ttm)
-4.46M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.1M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.48M
Research Analysis: ECX.F
Company Insights: ECX.F
ECX.F does not have Company Insights